Placebo use in vaccine trials: Recommendations of a WHO expert panel
نویسندگان
چکیده
Vaccines are among the most cost-effective interventions against infectious diseases. Many candidate vaccines targeting neglected diseases in low- and middle-income countries are now progressing to large-scale clinical testing. However, controversy surrounds the appropriate design of vaccine trials and, in particular, the use of unvaccinated controls (with or without placebo) when an efficacious vaccine already exists. This paper specifies four situations in which placebo use may be acceptable, provided that the study question cannot be answered in an active-controlled trial design; the risks of delaying or foregoing an efficacious vaccine are mitigated; the risks of using a placebo control are justified by the social and public health value of the research; and the research is responsive to local health needs. The four situations are: (1) developing a locally affordable vaccine, (2) evaluating the local safety and efficacy of an existing vaccine, (3) testing a new vaccine when an existing vaccine is considered inappropriate for local use (e.g. based on epidemiologic or demographic factors), and (4) determining the local burden of disease.
منابع مشابه
Regional advisory board position statement on optimal pneumococcal vaccination in adults. Update to 2011 consensus on adult pneumococcal disease: update on optimal pneumococcal vaccination in adults.
BACKGROUND An important development in the field of adult pneumococcal vaccination since the last Consensus Statement, published by the Expert Panel of Central and Eastern Europe and Israel (the Region) in September 2012, was the licensure of the 13-valent pneumococcal conjugate vaccine (PCV13) for adults aged 50 years and older. DISCUSSION The Expert Panel has developed this Position Stateme...
متن کامل"Guidelines for the clinical evaluation of dengue vaccines in endemic areas": summary of a World Health Organization Technical Consultation.
There is a pressing need for guidelines focused on the clinical evaluation of dengue vaccines in exposed populations, because Phase 1 and 2 clinical trials of dengue vaccines have begun, and Phase 3 field trials may be warranted soon. In response to this need, the WHO Initiative for Vaccine Research (IVR) has conducted a series of expert consultations resulting in guidelines published as a WHO;...
متن کاملDental management of patients receiving oral bisphosphonate therapy: expert panel recommendations.
BACKGROUND In light of the uncertainty surrounding the incidence of bisphosphonate-associated osteonecrosis of the jaw (BON) and concomitant risk factors, dentists have questioned how to manage the care of patients receiving oral bisphosphonate therapy. Expert panelists were selected by the American Dental Association Council on Scientific Affairs on the basis of their expertise in the relevant...
متن کاملHow to Meet the Last OIE Expert Surveillance Panel Recommendations on Equine Influenza (EI) Vaccine Composition: A Review of the Process Required for the Recombinant Canarypox-Based EI Vaccine
Vaccination is highly effective to prevent, control, and limit the impact of equine influenza (EI), a major respiratory disease of horses. However, EI vaccines should contain relevant equine influenza virus (EIV) strains for optimal protection. The OIE expert surveillance panel annually reviews EIV evolution and, since 2010, the use of Florida clade 1 and 2 sub-lineages representative vaccine s...
متن کاملDengue Vaccine Public Health Impact Evaluation
A number of resources are available which provide an insight on impact evaluation issues that could relate to CYD-TDV implementation. • The article from Lim, et al. “Points for Consideration for dengue vaccine introduction – recommendations by the Dengue Vaccine Initiative Expert Rev Vaccines; 2016 Apr;15 (4):529-38. doi: 10.1586/14760584.2016.1129279”, describes various elements to accelerate ...
متن کامل